Cancer

Natural product-derived therapy for Chronic Myeloid leukaemia (CML): a therapeutic mix encompassing Ivermectin and Curcumin decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloid leukemia via up-regulation of its target gene, 25/August/2017, 4.35 am
Natural product-derived therapy for Chronic Myeloid leukaemia (CML): a therapeutic mix encompassing Ivermectin and Curcumin decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloid leukemia via up-regulation of its target gene, 25/August/2017, 4.35 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Biochemistry-Molecular Biology, Franklin College of Arts and Sciences, The University of Georgia, Athens, Georgia 30602, USA; and The University of…

read more

Natural product-derived combinatorial therapy for therapy-resistant cancers: A therapeutic mix encompassing Berberine (BER), Gambogic acid and Curcumin (BGC) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via up regulation of its target gene, 24/August/2017, 12.33 am
Natural product-derived combinatorial therapy for therapy-resistant cancers: A therapeutic mix encompassing Berberine (BER), Gambogic acid and Curcumin (BGC) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via up regulation of its target gene, 24/August/2017, 12.33 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Broad Institute, Cambridge, Massachusetts, USA, Howard Hughes Medical Institute, Chevy Chase, Maryland and Department of Chemistry and Chemical Biology, Harvard University, Oxford St., Cambridge,…

read more

Molecular therapy for Metastatic cancers: Myrtenal, isolated  from Taxus, increases the expression of metastasis suppressors TIMP3 and CCM3/KRTI1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 24/August/2017, 12.24 am
Molecular therapy for Metastatic cancers: Myrtenal, isolated  from Taxus, increases the expression of metastasis suppressors TIMP3 and CCM3/KRTI1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 24/August/2017, 12.24 am 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance: Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

read more

Natural product/vitamin-based Combination therapy for PTEN-deficient cancer: A therapeutic mix encompassing Artemisinin, Cholecalciferol and Metformin decreases the expression of CHD1, increases the expression of a number of tumor suppressor genes, inhibits pro-survival TNF-NF-kB gene network, and suppresses tumorigenesis of PTEN-deficient cancer, 22/August/2017, 10.29 pm
Natural product/vitamin-based Combination therapy for PTEN-deficient cancer: A therapeutic mix encompassing Artemisinin, Cholecalciferol and Metformin decreases the expression of CHD1, increases the expression of a number of tumor suppressor genes, inhibits pro-survival TNF-NF-kB gene network, and suppresses tumorigenesis of PTEN-deficient cancer, 22/August/2017, 10.29 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA shows that “Synthetic essentiality of chromatin remodelling…

read more

Natural product-derived therapy for prostate cancer: A therapeutic mix encompassing N-Acetylcysteine(NAC), Capsaicin, and Sulforaphane (NCS) inhibits the expression of mTORC1 and its downstream target AMD1, dismantles mTORC1-AMD1 signaling network, decreases polyamine levels, and inhibits prostate cancer progression via up regualtion of its target gene, 22/July/2017, 10.08 pm
Natural product-derived therapy for prostate cancer: A therapeutic mix encompassing N-Acetylcysteine(NAC), Capsaicin, and Sulforaphane (NCS) inhibits the expression of mTORC1 and its downstream target AMD1, dismantles mTORC1-AMD1 signaling network, decreases polyamine levels, and inhibits prostate cancer progression via up regualtion of its target gene, 22/July/2017, 10.08 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from CIC bioGUNE (Center for Cooperative Research in Biosciences), Bizkaia Technology Park, 801 Building, 48160 Derio, Spain shows that “mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.” This…

read more

Natural product-derived therapy for gynecologic cancers: A therapeutic mix encompassing N-Acetylcysteine, Capsaicin, and Sulforaphane (NCS) inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers via up-regulation of its target gene, 21/August/2017, 11.58 am
Natural product-derived therapy for gynecologic cancers: A therapeutic mix encompassing N-Acetylcysteine, Capsaicin, and Sulforaphane (NCS) inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers via up-regulation of its target gene, 21/August/2017, 11.58 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA shows that “ARID1A-mutated ovarian cancers depend on HDAC6 activity” This study…

read more
Start Typing